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Drug Discovery and Development: biomarkers of neurotoxicity and neurodegeneration 
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Abstract 
The discovery and development of new drugs is vital if we are to improve and expand treatment 
options available to improve outcomes for patients.  Overall, therapeutic strategies fall into two 
broad categories: small molecules and biologics although more recently there has been a 
growth in novel platforms such as miRNAs and oligonucleotides.  On average the development 
of a small molecule drug takes around 12 years and costs around $50m.  Despite this huge 
investment of time and money, attrition remains a major challenge and very few molecules 
actually make it through to the market.  Here, we look at reasons for attrition in the small 
molecule field with a focus on neurotoxicology and efforts being made to improve success via 
the development of imaging and fluidic biomarkers.  We also look at learnings from other 
models of CNS damage and degeneration such as Parkinson’s Disease (PD), traumatic brain 
injury (TBI) and multiple sclerosis (MS) since these may offer the opportunity to improve tools 
available to nonclinical toxicologists in the early detection of potential neurotoxicity.  
Reciprocally, learnings from studies of animal neurotoxicity may offer better ways to potentially 
monitor patients during clinical development of new drugs for neurodegeneration.   
Impact statement 
Attrition in drug discovery and development remains a major challenge.  Safety/toxicity is the 
most prevalent reason for failure with cardiovascular and CNS toxicities predominating.  Non-
invasive biomarkers of neurotoxicity would provide significant advantage by allowing earlier 
prediction of likely neurotoxicity in preclinical studies as well as facilitating clinical trials of new 
therapies for neurodegenerative conditions such as Parkinson’s disease (PD) and multiple 
sclerosis (MS). 
  
Drug Discovery and Development: an overview 
Small molecule drug discovery begins with the selection of a target based on linkage of the 
target with disease, target expression across tissue and species and likely ‘drugability’ of the 
target (Figure 1).  Also important at this stage is a target safety assessment (TSA) to 
characterise the potential for unwanted side effects of target inhibition or activation. 1, 2   Once a 
target is selected, then the search for chemistry that can interact with the target begins usually 
via high throughput screening (HTS) of chemical collections containing millions of molecules.  
Options are narrowed down via exploration of the impact of chemical modification both on 
potency/selectivity and also on other key parameters such as solubility/partitioning.  This is the 
optimum time to run early safety screens such as genetic toxicology and the potential to form 
reactive metabolites since any liabilities can be designed out in an iterative design-make-test 
cycle.  This also applies to removing liability associated with hERG (human Ether-à-go-go-
Related Gene) since inhibition of potassium currents through this ion channel is linked to a 
potentially fatal cardiac arrhythmia called Torsades de Pointes.  Ultimately, one molecule is 
selected to go forward for GLP toxicology testing.  This is an expensive phase of drug 
development, costing on average $7m/molecule 3 and is pivotal in generating the data to ensure 
the safety of patients and volunteers is protected in the first time in human (FTIH) clinical trials.   
The majority of FTIH clinical trials are conducted in healthy male volunteers and are aimed at 
establishing tolerance, kinetics, pharmacology (proof of mechanism) and offer the opportunity to 
detect early signals of potential efficacy.  Small doses that would not be expected to cause any 
adverse outcome are used.  For drugs aimed at treating life threatening conditions such as 
cancer, phase I is conducted in late stage cancer patients where scheduling is also studied 
alongside tolerance, kinetics, pharmacology and potential early signals of efficacy.  For most 
cancer drugs, even low doses are likely to be associated with toxicities hence it would be 
unacceptable to expose healthy volunteers.   
Phase II takes place in groups of usually 100-500 patients and builds on earlier data on 
tolerance, kinetics and pharmacology to gain data on efficacy (proof of concept), dose range, 
and drug interactions.  Phase III typically studies thousands of patients and is aimed at 
generating the data for registration via double-blind trials against current standard of care 
looking at detailed measurements of efficacy and safety in a broader population.  
  
Navigating the Regulatory Framework 
The typical pattern of drug discovery and development is supported by a regulatory framework 
that aims to standardise the data sets needed to support each transition to ensure maximum 
efficiency while ensuring patient and volunteer safety is protected.  Briefly, specific International 
Council for Harmonisation (ICH) guidelines4 specify the different areas of testing to be 
undertaken to create the ‘FTIH package’ that is normally required for Phase 1 clinical trials, 
wherever they occur in the world (US, Europe, Japan, China, South America, India, etc.) (Figure 
2). 
In general toxicology, the FTIH decision is supported by two species toxicology testing, usually 
in the rat and dog.  A maximum tolerated dose (MTD) is established followed by a period (7-14 
days) of repeat dosing to ensure the proposed MTD can be sustained over the usual one-month 
period of testing (Figure 2).  A low dose is then chosen that is a likely no effect level and a mid-
dose is chosen to give a dose response.  In Europe, the start of the nonrodent studies is usually 
slightly staggered in case of any unexpected issues.   
In safety and secondary pharmacology, unwanted effects of the compounds are studied in a 
growing panel of likely unwanted targets (secondary pharmacology), starting with around 20 and 
building to >300 receptors, kinases, ion channels and others as the compound approaches 
FTIH.  At this preclinical stage, predicted margins to the intended target are used to guide 
chemistry towards efficacy and away from probable unwanted off-target effects. Safety 
pharmacology addresses the safety endpoints associated with the drug’s pharmacology in a so 
called ‘core battery’ that looks at the cardiovascular system (heart rate, blood pressure), CNS 
(locomotion, reflexes, pain threshold, seizure) and respiratory system.   
Genetic toxicology and carcinogenicity look at the potential of new drugs to cause cancer either 
through direct damage to DNA or via non-genotoxic mechanisms.  A sequence of in silico, in 
vitro and in vivo tests are used to detect and eliminate DNA-damaging molecules wherever 
possible.  Generally, a positive in one of these assays (ie the compound damages DNA) would 
be a stop for a compound unless interaction with DNA is key to efficacy, as expected with some 
anti-cancer drugs.  Drugs that are negative in genetic toxicology testing can progress through 
phase I and phase II clinical trials and into phase III for some types of treatment.   
Beyond FTIH, chronic toxicology studies of >3 months are generally needed to support longer 
term clinical dosing, since for conventional development of pharmaceuticals the clinical trial 
duration cannot exceed the duration of the toxicology cover (Figure 3).  This is not the case for 
oncology drug development; there are also other key differences in the approach to 
conventional versus oncology drug development especially around starting and limit doses and 
the need for genetic toxicology and carcinogenicity testing (Figure 3).  However, if chronic 
dosing is intended then carcinogenicity testing is normally required for a marketing authority 
authorisation (MAA) (Figure 3).   
Although the toxicology studies conducted to support entry to phase I clinical trials generally 
follow guidelines, these guidelines are open to interpretation using good science and sound 
decision making.  Also notable is that the probability of success of drug projects can be 
considerably enhanced by early, bespoke science aimed at derisking target and chemistry.  A 
target safety assessment (TSA) would provide a thorough review of the likely unintended 
consequences of inhibiting or activating a specific target and should be used alongside the 
traditional thorough understanding of target biology and disease linkage. 1, 2  Derisking 
chemistry would focus on eliminating obvious risks such as genetic toxicology and functional 
interaction with ion channels associated with cardiovascular liability such as hERG. 5  It is vital 
that these assays are performed early in the lead optimisation process while there is still choice 
in chemistry and in a time frame compatible with the design-make-test cycle that is a key part of 
lead generation, lead optimisation and candidate selection.   
 
Attrition in drug discovery and development: prevalence of neurotoxicity 
Safety-related attrition remains a major issue in drug discovery and development.   The most 
frequent reason for candidate drugs falling out of development is cardiovascular risk; much has 
been done to address this over recent years with huge investments in understanding the 
molecular basis for arrythmia leading to the advent of hERG screening5 and the more recent 
CiPA initiative. 6   However, failure due to CNS toxicity is also a predominant occurrence; Figure 
4 (derived from data in an analysis of reasons for failure in the AstraZeneca portfolio7) shows 
that CNS toxicity accounts for nearly one quarter of failures across the whole spectrum of 
discovery and development (Figure 4B); however, it is a relatively infrequent finding during GLP 
toxicology (Figure 4A). 3  As highlighted in Figure 4C, this puts the burden of failures into clinical 
development where consequences are higher in terms of resources and patient impact.  
Interestingly, CNS toxicity peaks in drugs intended for CNS indications (Figure 4D) possibly 
because CNS drugs are deliberately CNS penetrant whereas this property is often avoided for 
other indications if at all possible.  However, CNS toxicity is also frequent in the cardiovascular 
and gastrointestinal (CVGI) therapy areas. 7   A related study that looked at attrition data for a 
broader compound set from AstraZeneca, Ely Lilly, GlaxoSmithKline and Pfizer confirmed that 
nonclinical toxicology was the primary cause for failure in drug discovery and development 8.  
However this paper did not provide an analysis of target organ systems so cannot be used to 
validate or refute the AstraZeneca findings on relative frequency of CNS findings.   
Neurotoxicities noted in registered drugs 
As well as the issue of attrition due to neurotoxicity, many registered medicines also carry so 
called ‘black box warnings’ of neurotoxicity, a name taken from the black border around the 
labelling information intended to alert consumers and healthcare professionals to potential risks.  
The recent publication of FDALabel 9 allows an analysis of the most frequent neurotoxicities 
noted in NDAs.  Of the around 37 000 human prescription drugs included in FDALabel, around 
400 carry black box warnings for neurotoxicity and related issues.  The most frequent findings 
were suidical ideation and sedation followed by abuse liability, seizure/convulsion and headache 
(Figure 5).     
 
Categories of Neurotoxicity: challenges for detection and prediction  
As highlighted by data on attrition and as evidenced by black box warnings for registered 
medicines, neurotoxicity remains a major issue in drug discovery and development.  However, 
when considering the utility of current and future potential methods of detection, prediction and 
clinical monitoring, it is important to distinguish structural from functional neurotoxicity.  Broadly 
speaking, structural neurotoxicity is associated with tissue damage whereas functional 
neurotoxicity may be associated with electrical activity (seizure/convulsions) or could be a 
manifestation of perturbations in higher brain function such as depression or suicidal ideation.  
Because of the different methodologies and endpoints studied in animal studies versus the 
clinic, structural damage to the CNS detected by histopathology or functional endpoints such as 
seizure form the majority of neurotoxicities reported in rodent and nonrodent toxicology studies.  
In contrast, in the clinic the majority of neurotoxicities are functional in nature (suicidal ideation, 
depression, headache) with the exception of retinal/ocular toxicity, a relatively infrequent finding 
(2/400) 9 but one with clear structural correlates. 
Current and emerging approaches to detect neurotoxicity and abnormal neurological 
function.   
Functional neurotoxicity has major challenges for detection in any model system.  Issues such 
as abuse liability and suicidal ideation are especially challenging but other toxicities such as 
sedation and seizure may be more amenable to earlier detection. Current methods usually rely 
on observations made in the nonclinical rodent and non-rodent studies required to support 
clinical trials. These could be central nervous system (CNS)-related signs such as tremors or 
other abnormal movements, but these signs can be misdiagnosed or misinterpreted by 
inexperienced operators.  Thus, confirmation of drug-induced seizure or seizure-like activity 
requires a follow-up electroencephalogram (EEG) study.  Some progress has been made in in-
life detection of seizure using automated video systems that record and analyze animal 
movements, looking for abnormalities.  Nonetheless, it would be far preferable to have an earlier 
prediction of seizurogenic risk that could be used to eliminate liabilities early in discovery while 
there are still options in chemistry.  Early identification of these risks using cheaper, higher 
throughput and more predictive assays that both reduce and/or avoid animal use and have 
lower compound requirements would be preferable.  
Over the last decade, several assays that are compatible with the design-make-test-analyze 
cycle of drug discovery have become available. Regarding seizure, two approaches offer 
exciting opportunities:  microelectrode array is now able to detect seizurogenic signals in iPSC-
derived Cortical Neural Stem Cells differentiated to electrically active cortical neurons.  This 
offers great potential to screen for seizurogenic liability in an in vitro system.  A second 
approach could be based on an understanding of the neuronal ion channels implicated in the 
seizurogenic response.  Recently, some progress has been made in developing these in vitro 
seizure models and there is a developing interest in characterizing the ion channels both at the 
expressional and at the functional level.   However, much of the current research on avoiding 
neurotoxicity is focused on structural endpoints since the associated tissue damage provides 
more opportunity for detection via fluidic biomarkers and imaging.  
Detection of neurotoxicity: development of fluidic biomarkers 
Back in 2012, the Health and Environmental Sciences Institute (HESI)10 initiated a project to 
enhance preclinical detection of CNS toxicity.  The development of biomarkers of neurotoxicity 
is a goal shared by scientists across academia, government, and industry and as such was an 
ideal topic to be addressed via HESI.   The project goal was to determine if there are more 
sensitive and speciﬁc biomarkers that could help diagnose and predict neurotoxicity.  These 
biomarkers would also be of additional use if they were relevant across animal models and also 
could be translated from nonclinical to clinical data.  Additionally, it is relatively easy to sample 
fluid-based biomarkers in serum, plasma, urine, and cerebrospinal ﬂuid (CSF) compared with 
taking tissues.    
The HESI Biomarkers of Neurotoxicology Committee (NeuTox)11 met on several occasions to 
define scope and to propose an experimental model to address the challenge.   Several 
experimental models were considered but on balance the committee selected trimethyl tin 
(TMT) in rat for a variety of reasons; the rat is the rodent species of choice in preclinical testing 
and the lesion induced in the rat hippocampus by TMT is well characterised. 12  The prodrug 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was also considered; MPTP is a prodrug to 
the neurotoxin MPP+, which causes permanent symptoms of Parkinson's disease in the mouse 
by destroying dopaminergic neurons in the substantia nigra of the brain.  However, MPTP is 
ineffective in the rat and as such is not as relevant to models of drug discovery and 
development.   A key aspect of the project was to link the expression of the fluidic biomarkers of 
interest to imaging and functional parameters but importantly to traditional histopathology 
endpoints (Figure 6). 12 
Rats were given a single dose of TMT and were analysed at 2, 6, 10 and 14 days.  Brain, liver, 
thymus, adrenal, kidney, spinal cord and sciatic nerve tissue was sampled along with biological 
fluids (CSF, plasma, serum and urine). 13  Many fluid-based biomarkers were considered for 
analysis such as microRNAs, F2-isoprostanes, translocator protein, glial ﬁbrillary acidic protein 
(GFAP), ubiquitin C-terminal hydrolase L1, myelin basic protein, microtubule-associated protein-
2, and total tau.  In addition, several neuroimaging methodologies were employed including 
magnetic resonance imaging, magnetic resonance spectroscopy, and positron emission 
tomography.   
 Results of this study showed promising correlations between GFAP, specific miRNAs, some 
metabolites such as biogenic amines and phospholipids and T2 relaxation in the hippocampus 
measured by Magnetic Resonance Imaging (MRI). 13  T2 relaxation is associated with lateral 
ventricle volume change which in turn is associated with  damage-induced fluid accumulation 
both in humans and in animal models.  Overall, the results so far show that we have found ways 
to identify neurotoxic damage in fluids (CSF, plasma and serum) in this TMT-induced model of 
neurological damage.  13   Additional analyses including bioinformatics are underway along with 
analysis of other potential biomarkers arising from other studies of brain damage (see table 1).  
Learnings from these studies of brain damage and of disease models offer the opportunities to 
improve the tools available to nonclinical toxicologists in the early detection of potential 
neurotoxicity as well as better ways to potentially monitor patients during clinical development.  
Potential Use of CNS Biomarkers in the Clinic – Traumatic Brain Injury (TBI) 
The Center for Disease Control and Prevention estimates that in 2013 TBI contributed to the 
deaths of some 50 000 people. 14 In 2012, more than 300 000 people under the age of 19 
sought emergency room treatment for TBI resulting from sport or recreation injury.  Thus, TBI is 
a big issue that especially impacts the younger demographic.  GFAP has been proposed as a 
marker of TBI15 and in a recent exciting development, the FDA has approved GFAP as a test for 
TBI that could be used to monitor biochemical changes in patients and gauge the response to 
treatment. 16 As well as GFAP as mentioned earlier, UCH-L1 is also cited as a potential marker 
to be measured in serum as a diagnostic for mild TBI. 16  These markers are recommended to 
be used as an acute diagnostic (within 12 hours) of when a CT scan maybe required to detect 
concussion.  It will be interesting to see if UCH-L1 is expressed in the TMT model alongside the 
biomarkers already detected (miRNAs, biogenic amines and phospholipids).   
 
Potential use of CNS Biomarkers in the Clinic – Neurodegenerative disorders 
Although the fluidic biomarkers mentioned above were detected and validated in a toxicant 
model, there is a possibility they could be useful in clinical development of new treatments for 
neurodegenerative and other neurological disorders such as Parkinson’s and Multiple Sclerosis.  
Currently, is it very difficult to detect a signal for efficacy for such conditions in early clinical 
trials; the duration of experimental new drug treatments may be limited to one month by the 
toxicology cover since the chronic (>3 month) toxicology studies needed to support longer term 
exposure are not conducted until later in a drug development programme.  Additionally, patients 
may have advanced and complex disease conditions, having failed other therapies.  Any 
biomarker that could provide evidence of a potential for therapeutic benefit would be very helpful 
in this context.  But is it realistic to anticipate cross-over from biomarkers noted in a TMT 
toxicant model and such disease conditions?  To answer this, we can look at commonly used 
animal models and their translation. 
 
Animal models of Parkinson’s 
Parkinson's disease is a progressive disorder of the nervous system that affects movement.  17 
It develops gradually, sometimes starting with a barely noticeable tremor in just one hand. But 
while a tremor may be the most well-known sign of Parkinson’s disease, the disorder also 
commonly causes stiffness or slowing of movement.   As with many models of 
neurodegenerative disease, models of Parkinson’s are based on either toxicant administration 
or on gene deletion or addition.  As with all models, they have their limitations, making it 
important to select the optimal in vitro or in vivo model for the question being asked where any 
weaknesses will not invalidate the interpretation of an experiment.  
 
One of the most widely used toxicant models is MPTP in mice and monkeys and rotenone in 
rats and mice.  17  Although the MPTP neurotoxic model has advantages, one notable departure 
is that the degeneration of dopaminergic neurons progress rapidly, taking days and not years as 
would be seen in human disease.  Additionally, lesions are primarily dopaminergic and lack the 
typical PD proteinaceous inclusions called Lewy bodies (LBs).  On the positive side, MPTP has 
been shown to be toxic in a large range of species.  Chronic systemic exposure to rotenone in 
rats causes many features of PD, including nigrostriatal dopaminergic (DA) degeneration.  The 
rotenone-administered animal model also reproduces all of the behavioral features reminiscent 
of human PD. Importantly, many of the degenerating neurons have intracellular inclusions that 
resemble LB morphologically. More recently, rotenone has also been tested in mice 
recapitulating the slow and specific loss of DA neurons.  
In speculating that fluidic and imaging biomarkers detected in the rodent TMT study may be 
relevant to PD, it’s worth noting that MPTP is frequently used as a model neurotoxicant as well 
as a model compound for inducing PD-like symptoms.   These commonalities suggest that 
looking for the biomarkers noted in figure 5 in models of PD and in clinical samples is a 
worthwhile step. Detection of UCH-L1 in CSF and the possibility of detection in serum/plasma 
may offer a specific biomarker of great use in PD models. 18 
Animal models of multiple sclerosis 
Multiple sclerosis (MS) is a serious and debilitating disease with variable progression patterns 
and symptom manifestation. 19 Development of effective treatment strategies is supported by 
qualitative in vivo research efforts which seek to examine related disease pathologies from 
cellular components up to large-scale whole system appraisal in the form of an animal model. 
As with other models of neurodegenerative diseases, MS can be modelled by demyelination 
with a toxin such as cuprizone and lyso-phosphatidyl choline (lyso-lecithine). However, one of 
the most widely studied models is experimental autoimmune encephalomyelitis (EAE).  EAE is a 
term used to describe a collection of inflammatory disorders which develop upon immunisation 
with antigens derived from CNS proteins - a process that induces an autoimmune response. It 
was first induced experimentally in 193320 and at its most basic level leads to progressive 
paralysis with B and T cell activation cumulating in white matter lesions. 21  Interestingly, EAE 
can be combined with other MS induction protocols such as cuprizone dosing. This toxin 
induces demyelination of the CNS and, when combined with EAE, generates an in vivo MS 
model that encompasses multiple pathological elements. 22 
Looking at other types of progressive neurodegenerative disease such as amyotrophic lateral 
sclerosis (ALS), miR-218a-5p, a brain enriched miRNA has been described as a clinically useful 
marker of ALS progression.  23, 24  Notably, this specific miRNA was readily detectable in the rat 
TMT model described earlier. 13   These data suggest that such miRNAs could be very useful 
biomarkers of overall CNS toxicity and as such applicable to earlier detection of CNS signs in 
nonclinical animal studies. 
Conclusions 
Identifying neurotoxicity in drug discovery and development can improve outcomes in a number 
of ways, including increasing our efficiency and accuracy of diagnosis and our ability to 
intervene with pharmaceutical treatments. Early identification of neurotoxicity enables early 
intervention, which improves outcomes. Utilization of biomarkers of neurotoxicity also allows for 
continual monitoring of disease states and drug efficacy and, thus, may improve disease 
management. From a therapeutic standpoint, detecting and predicting neurotoxicity in preclinical 
(testing phase before new drugs enter the clinic) and nonclinical (testing of nondrug entities at 
all phases or ongoing testing of drugs in parallel to clinical development) models can improve 
decision making during drug development.  Functional endpoints such as seizure and sedation 
may be amenable to earlier detection with some of the in vitro and in vivo developing 
methodologies such as in cage monitoring and microelectrode array detection of cellular 
electrical activity.  However, higher order brain function endpoints such as suicidal ideation and 
depression remain a challenge for the foreseeable future.  Because of this, much of the current 
research is focused on improving detection of structural change via imaging and fluidic 
biomarkers.  Studies of toxicity models have provided a panel of possible biomarkers, 
supplemented with learnings from damage and disease models such as TBI and MS.   
Reciprocally, these toxicity biomarkers may provide the opportunity for earlier detection of 
efficacy in clinical trials of new medicines for Alzheimer’s, Parkinson’s and other 
neurodegenerative conditions.  Overall, such approaches should form part of a rationale 
stepwise cascade of screening to identify, mitigate and manage risk using in silico, in vitro and 
in vivo methodologies.   
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Figure 1.  The drug discovery and development paradigm for small molecules. Target selection 
(TS) is followed by lead generation (LG) and lead optimisation (LO).  One or two candidate 
drugs (CDs) are selected to begin more extensive in vitro and in vivo testing, providing the data 
to select one molecule to go forward for good laboratory practice ( GLP) toxicology testing in 
support of first time in human (FTIH) clinical trials.   
 
 
Figure 2.  Navigating the regulatory framework.   International Council for Harmonisation (ICH) 
guidelines specify the different areas of testing to be undertaken to create the ‘FTIH package’.  
Testing is structured as general toxicology, safety and secondary pharmacology, genetic 
toxicology/carcinogenicity and developmental/reproductive toxicology.    CD: candidate drug; 
CNS: Central Nervous System; DRF: dose range finding; EFD: Embryo Fetal Development; 
FTIH: first time in human; GLP: good laboratory practice; LG/LO: lead generation/lead 
optimization; ICH: International Council for Harmonization; MOLY: Mouse Lymphoma; MTD: 
maximum tolerated dose; P&P: peri and post-natal; SAR: Structure Activity Relationship; TS: 
target selection.  *: could be different duration or cyclical dosing depending on clinical plan. 
 
Figure 3.  A comparison of key aspects of ICH M3 and ICH S9.  See text for details.  PK: 
pharmacokinetics; MAA: marketing authority authorization. 
 
Figure 4.  An analysis of reasons for attrition in drug development.  A.  Safety failures during 
GLP toxicology testing show that CNS toxicity is infrequent.  B.  Safety failures across all 
discovery and development stages demonstrates that CNS accounts for almost 25% of failures.  
C. Clinical failures predominate over preclinical failures.  The CNS therapy area predominates in 
the overall failure profile due to CNS toxicity but CVGI and R&I are also impacted.  For original 
data see Cook et al., 2014. 7 
Figure 5.  Incidence of neurotoxicities reported in the FDALabel database 9.  FDALabel provides a 
concise overview of US Food and Drug Administration (FDA) drug labeling, which details drug products, 
drug-drug interactions, adverse drug reactions (ADRs) and contains a set of approximately 80000 data 
labels.    
Figure 6.  Correlation of biomarkers in the rat TMT model with imaging and histopathological 
endpoints.   In MRI, magnetic pulses perturb the orientation of protons (typically hydrogen 
atoms) and the instrument records the time it takes for the perturbed protons to return or relax to 
their pre-perturbed state. Longitudinal relaxation time is referred to as T1 and transverse 
relaxation time as T2.   Fluorojade C (FJC) is a marker for dead neurones.  GFAP: green 
fibrillary acidic protein; MRI: magnetic resonance imaging.   
 
